secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0000950170-22-000180
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics reports preliminary cash of $133.5M as of Dec 31, 2021
-------------------------------------------------------------------------

- Preliminary cash and cash equivalents of approximately $133.5M as of Dec 31, 2021.
- CEO Mark Smith to present at J.P. Morgan Healthcare Conference on Jan 13, 2022.
- Updated corporate presentation posted on company website for investor meetings.
- Year-end audit ongoing; final cash balance may differ from preliminary estimate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/0000950170-22-000180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017022000180/fnch-20220110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer